Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Single Center Study of an Individualized Antisense Oligonucleotide Treatment for Retinal Dystrophy Associated With a Pathogenic PRPH2 Variant

NCT07177196 is registered in ClinicalTrials.gov with n-Lorem Foundation as lead sponsor.

NCT NCT07177196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07177196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Single Center Study of an Individualized Antisense Oligonucleotide Treatment for Retinal Dystrophy Associated With a Pathogenic PRPH2 Variant
Lead sponsor
n-Lorem Foundation
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 28, 2025
Completion date
August 31, 2027
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

retinal dystrophy